Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 29

1.

Combined MEK and BCL-2/XL Inhibition Is Effective in High-Grade Serous Ovarian Cancer Patient-Derived Xenograft Models and BIM Levels Are Predictive of Responsiveness.

Iavarone C, Zervantonakis IK, Selfors LM, Palakurthi S, Liu JF, Drapkin R, Matulonis UA, Hallberg D, Velculescu VE, Leverson JD, Sampath D, Mills GB, Brugge JS.

Mol Cancer Ther. 2019 Mar;18(3):642-655. doi: 10.1158/1535-7163.MCT-18-0413. Epub 2019 Jan 24.

PMID:
30679390
2.

BRAF and AXL oncogenes drive RIPK3 expression loss in cancer.

Najafov A, Zervantonakis IK, Mookhtiar AK, Greninger P, March RJ, Egan RK, Luu HS, Stover DG, Matulonis UA, Benes CH, Yuan J.

PLoS Biol. 2018 Aug 29;16(8):e2005756. doi: 10.1371/journal.pbio.2005756. eCollection 2018 Aug.

3.

Systems analysis of apoptotic priming in ovarian cancer identifies vulnerabilities and predictors of drug response.

Zervantonakis IK, Iavarone C, Chen HY, Selfors LM, Palakurthi S, Liu JF, Drapkin R, Matulonis U, Leverson JD, Sampath D, Mills GB, Brugge JS.

Nat Commun. 2017 Aug 28;8(1):365. doi: 10.1038/s41467-017-00263-7.

4.

Endothelial monolayer permeability under controlled oxygen tension.

Funamoto K, Yoshino D, Matsubara K, Zervantonakis IK, Funamoto K, Nakayama M, Masamune J, Kimura Y, Kamm RD.

Integr Biol (Camb). 2017 Jun 19;9(6):529-538. doi: 10.1039/c7ib00068e.

PMID:
28488717
5.

Establishment of Patient-Derived Tumor Xenograft Models of Epithelial Ovarian Cancer for Preclinical Evaluation of Novel Therapeutics.

Liu JF, Palakurthi S, Zeng Q, Zhou S, Ivanova E, Huang W, Zervantonakis IK, Selfors LM, Shen Y, Pritchard CC, Zheng M, Adleff V, Papp E, Piao H, Novak M, Fotheringham S, Wulf GM, English J, Kirschmeier PT, Velculescu VE, Paweletz C, Mills GB, Livingston DM, Brugge JS, Matulonis UA, Drapkin R.

Clin Cancer Res. 2017 Mar 1;23(5):1263-1273. doi: 10.1158/1078-0432.CCR-16-1237. Epub 2016 Aug 29.

6.

Growth inhibition in a brain metastasis model by antibody delivery using focused ultrasound-mediated blood-brain barrier disruption.

Kobus T, Zervantonakis IK, Zhang Y, McDannold NJ.

J Control Release. 2016 Sep 28;238:281-288. doi: 10.1016/j.jconrel.2016.08.001. Epub 2016 Aug 3.

7.

Mutant p53 regulates ovarian cancer transformed phenotypes through autocrine matrix deposition.

Iwanicki MP, Chen HY, Iavarone C, Zervantonakis IK, Muranen T, Novak M, Ince TA, Drapkin R, Brugge JS.

JCI Insight. 2016 Jul 7;1(10). pii: 86829. doi: 10.1172/jci.insight.86829.

8.

A protein interaction map for cell-cell adhesion regulators identifies DUSP23 as a novel phosphatase for β-catenin.

Gallegos LL, Ng MR, Sowa ME, Selfors LM, White A, Zervantonakis IK, Singh P, Dhakal S, Harper JW, Brugge JS.

Sci Rep. 2016 Jun 3;6:27114. doi: 10.1038/srep27114.

9.

Neutrophils Suppress Intraluminal NK Cell-Mediated Tumor Cell Clearance and Enhance Extravasation of Disseminated Carcinoma Cells.

Spiegel A, Brooks MW, Houshyar S, Reinhardt F, Ardolino M, Fessler E, Chen MB, Krall JA, DeCock J, Zervantonakis IK, Iannello A, Iwamoto Y, Cortez-Retamozo V, Kamm RD, Pittet MJ, Raulet DH, Weinberg RA.

Cancer Discov. 2016 Jun;6(6):630-49. doi: 10.1158/2159-8290.CD-15-1157. Epub 2016 Apr 12.

10.

Controlled Drug Release and Chemotherapy Response in a Novel Acoustofluidic 3D Tumor Platform.

Zervantonakis IK, Arvanitis CD.

Small. 2016 May;12(19):2616-26. doi: 10.1002/smll.201503342. Epub 2016 Mar 31.

11.

Controlled electromechanical cell stimulation on-a-chip.

Pavesi A, Adriani G, Rasponi M, Zervantonakis IK, Fiore GB, Kamm RD.

Sci Rep. 2015 Jul 2;5:11800. doi: 10.1038/srep11800.

12.

Biomimetic tissue-engineered systems for advancing cancer research: NCI Strategic Workshop report.

Schuessler TK, Chan XY, Chen HJ, Ji K, Park KM, Roshan-Ghias A, Sethi P, Thakur A, Tian X, Villasante A, Zervantonakis IK, Moore NM, Nagahara LA, Kuhn NZ.

Cancer Res. 2014 Oct 1;74(19):5359-63. doi: 10.1158/0008-5472.CAN-14-1706. Epub 2014 Aug 5.

13.

Synergistic effects of 3D ECM and chemogradients on neurite outgrowth and guidance: a simple modeling and microfluidic framework.

Srinivasan P, Zervantonakis IK, Kothapalli CR.

PLoS One. 2014 Jun 10;9(6):e99640. doi: 10.1371/journal.pone.0099640. eCollection 2014.

14.

In vitro model of tumor cell extravasation.

Jeon JS, Zervantonakis IK, Chung S, Kamm RD, Charest JL.

PLoS One. 2013;8(2):e56910. doi: 10.1371/journal.pone.0056910. Epub 2013 Feb 20.

15.

Engineering of in vitro 3D capillary beds by self-directed angiogenic sprouting.

Chan JM, Zervantonakis IK, Rimchala T, Polacheck WJ, Whisler J, Kamm RD.

PLoS One. 2012;7(12):e50582. doi: 10.1371/journal.pone.0050582. Epub 2012 Dec 4.

16.

Screening therapeutic EMT blocking agents in a three-dimensional microenvironment.

Aref AR, Huang RY, Yu W, Chua KN, Sun W, Tu TY, Bai J, Sim WJ, Zervantonakis IK, Thiery JP, Kamm RD.

Integr Biol (Camb). 2013 Feb;5(2):381-9. doi: 10.1039/c2ib20209c.

17.

A novel microfluidic platform for high-resolution imaging of a three-dimensional cell culture under a controlled hypoxic environment.

Funamoto K, Zervantonakis IK, Liu Y, Ochs CJ, Kim C, Kamm RD.

Lab Chip. 2012 Nov 21;12(22):4855-63. doi: 10.1039/c2lc40306d.

18.

Tumor cell migration in complex microenvironments.

Polacheck WJ, Zervantonakis IK, Kamm RD.

Cell Mol Life Sci. 2013 Apr;70(8):1335-56. doi: 10.1007/s00018-012-1115-1. Epub 2012 Aug 25. Review.

19.

Three-dimensional microfluidic model for tumor cell intravasation and endothelial barrier function.

Zervantonakis IK, Hughes-Alford SK, Charest JL, Condeelis JS, Gertler FB, Kamm RD.

Proc Natl Acad Sci U S A. 2012 Aug 21;109(34):13515-20. doi: 10.1073/pnas.1210182109. Epub 2012 Aug 6.

20.

Microfluidic assay for simultaneous culture of multiple cell types on surfaces or within hydrogels.

Shin Y, Han S, Jeon JS, Yamamoto K, Zervantonakis IK, Sudo R, Kamm RD, Chung S.

Nat Protoc. 2012 Jun 7;7(7):1247-59. doi: 10.1038/nprot.2012.051.

21.

Ensemble analysis of angiogenic growth in three-dimensional microfluidic cell cultures.

Farahat WA, Wood LB, Zervantonakis IK, Schor A, Ong S, Neal D, Kamm RD, Asada HH.

PLoS One. 2012;7(5):e37333. doi: 10.1371/journal.pone.0037333. Epub 2012 May 25.

22.

Spectrally resolved multidepth fluorescence imaging.

Luo Y, Zervantonakis IK, Oh SB, Kamm RD, Barbastathis G.

J Biomed Opt. 2011 Sep;16(9):096015. doi: 10.1117/1.3626211.

23.

Microfluidic devices for studying heterotypic cell-cell interactions and tissue specimen cultures under controlled microenvironments.

Zervantonakis IK, Kothapalli CR, Chung S, Sudo R, Kamm RD.

Biomicrofluidics. 2011 Mar 30;5(1):13406. doi: 10.1063/1.3553237.

24.

A high-throughput microfluidic assay to study neurite response to growth factor gradients.

Kothapalli CR, van Veen E, de Valence S, Chung S, Zervantonakis IK, Gertler FB, Kamm RD.

Lab Chip. 2011 Feb 7;11(3):497-507. doi: 10.1039/c0lc00240b. Epub 2010 Nov 25.

PMID:
21107471
25.

Microfluidics: surface-treatment-induced three-dimensional capillary morphogenesis in a microfluidic platform (adv. Mater. 47/2009).

Chung S, Sudo R, Zervantonakis IK, Rimchala T, Kamm RD.

Adv Mater. 2009 Dec 18;21(47). doi: 10.1002/adma.200990175. No abstract available.

PMID:
21053389
26.

Surface-treatment-induced three-dimensional capillary morphogenesis in a microfluidic platform.

Chung S, Sudo R, Zervantonakis IK, Rimchala T, Kamm RD.

Adv Mater. 2009 Dec 18;21(47):4863-7. doi: 10.1002/adma.200901727. No abstract available.

PMID:
21049511
28.

Transport-mediated angiogenesis in 3D epithelial coculture.

Sudo R, Chung S, Zervantonakis IK, Vickerman V, Toshimitsu Y, Griffith LG, Kamm RD.

FASEB J. 2009 Jul;23(7):2155-64. doi: 10.1096/fj.08-122820. Epub 2009 Feb 26.

29.

A novel, view-independent method for strain mapping in myocardial elastography: eliminating angle and centroid dependence.

Zervantonakis IK, Fung-Kee-Fung SD, Lee WN, Konofagou EE.

Phys Med Biol. 2007 Jul 21;52(14):4063-80. Epub 2007 Jun 11.

PMID:
17664595

Supplemental Content

Loading ...
Support Center